About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Alba Simats Oriol, MSCA postdoctoral researcher at Institute of Biomedical Research at the Spanish Research Council (CSIC),
Abstract: Stroke leads to a significant medical burden, not just from brain injury itself but also due to subsequent secondary complications and comorbidities. By exploring the systemic immunological consequences of stroke, we found that myeloid innate immune memory contributes to secondary peripheral organ dysfunction after stroke. Using single-cell sequencing, we observed persistent pro-inflammatory changes in resident monocytes/macrophages across multiple peripheral organs up to three months after stroke, which were particularly abundant in the heart and associated with the development of chronic cardiac fibrosis and diastolic dysfunction. We identified IL-1b as the key driver of epigenetic changes contributing to innate immune memory post-stroke. By targeting IL-1â or blocking pro-inflammatory monocyte trafficking, we prevented post-stroke cardiac dysfunction, suggesting potential immune-focused therapies. These findings could offer insights into IL-1â-mediated comorbidities and innate immune reprogramming post-stroke, potentially aiding in understanding and preventing stroke-related health complications.
Host: Dr. Anna Rosell Novel, Head of group, Neurovascular Diseases (VHIR)
Register here to attend by Zoom:
https://gencat.zoom.us/webinar/register/WN_H3qMT24iRf6nsjq3YkCjog